




RealRate

PHARMACEUTICAL 2018

Altimmune Inc.
Rank 167 of 342





RealRate

PHARMACEUTICAL 2018

Altimune Inc.
Rank 167 of 342



The relative strengths and weaknesses of Altimune Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Altimune Inc. compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 167% points. The greatest weakness of Altimune Inc. is the variable Other Expenses, reducing the Economic Capital Ratio by 60% points.

The company's Economic Capital Ratio, given in the ranking table, is 100%, being 55% points above the market average of 46%.

Input Variable	Value in 1000 USD
Assets, Current	23,466
Cost of Goods Sold	0
Intangible Assets	38,722
Liabilities, Current	3,840
Liabilities, Non-Current	0
Other Assets	239
Other Compr. Net Income	2,998
Other Expenses	30,281
Other Liabilities	10,513
Other Net Income	-19
Other Revenues	10,738
Property and Equipment	603
Research and Development	18,406
Selling, General and Administrative Expense	8,458

Output Variable	Value in 1000 USD
Assets	63,030
Liabilities	14,353
Expenses	57,145
Revenues	10,738
Stockholders Equity	48,678
Net Income	-46,425
Comprehensive Net Income	-44,926
Economic Capital Ratio	100%